
*For relative performance of particular Investment Approach to other Portfolio Managers within the selected strategy, please refer https://www.apmiindia.org/
Consistent Compounders Portfolio (CCP)
For the quarter ended December 2023 (i.e. 3QFY24), earnings growth of CCP portfolio companies continued to accelerate further. Weighted average EPS growth was 36% YoY during the quarter for the portfolio. On the one hand, this growth was higher than the long term expected run-rate of earnings growth due to normalization of margins in 3QFY24 for companies like Page Industries, Dr. Lal Pathlabs, Asian Paints, Pidilite etc – margins in 3QFY23 for these companies were suppressed by either the reversal of Covid tailwinds during FY23 or by higher input costs last year. On the other hand, EPS growth in 3QFY24 for most of our portfolio companies also reflected market share gains, accelerate business development and hence robust revenue growth compared to competitors in the industry – e.g. Trent, Titan, Bajaj Fiannce, Astral, Dr. Lal etc.
As highlighted in our recent (3rd Feb) webinar, the ROE premium (measure of cash generation) and EPS growth premium of our portfolio companies compared to Nifty50 has been maintained across the last decade, including the last couple of years. However, the P/E premium of our portfolio companies has crunched down to a decadal low. Over the past five years, we have seen earnings compounding (measured by 1 year forward EPS expectation) being significantly ahead of share price compounding for all the three CCP lenders and the two CCP insurance companies. This presents a significant opportunity for catch-up of share prices with their fundamentals in the months and year to come. Amongst the non-financial sector companies, several companies (e.g. Titan, Trent and Astral) have significantly strengthened their business growth prospects over the last 5 years by transitioning from say a single product or retail format players (Tanishq for Titan, Westside for Trent, and Pipes for Astral) to a wider platform of products (Watches and Caratlane for Titan, Zudio and StarBazaar for Trent and Adhesives for Astral). Whilst the market had appreciated some of this transition in the first three out of the last five years, the share prices of these companies have also lagged significantly behind their fundamentals over the last two years – creating opportunities for outsized gains in the years to come. Finally, for companies such as Divis Labs, Dr. Lal Pathlabs and Page Industries, the wake effect of the Covid (i.e. reversal of some of the tailwinds that these companies witnessed during Covid) is behind us. From 3QFY24 onwards, for all these three companies, we can see more normal like to like growth rates and hence recovery in fundamentals is likely to get reflected in their share prices.
Last but not the least, we have increased our agility of portfolio construction tools over the last two years, the benefits of which are already visible in the strong positive contribution of position sizing changes to the performance of our portfolio over this period. We strive to keep learning from our mistakes and grab greater opportunities to enhance the performance of CCP in future. We expect the recovery in our portfolio performance since 1st April 2023 to continue over the next 12-24 months.


Kings of Capital Portfolio (KCP)
All KCP portfolio companies have reported results for the quarter ended Dec, 2024. As we have always stated, quarterly results provide a good checkpoint to analyse how our investee companies are doing versus competition and rest of the industry. Companies in our portfolio reported healthy fundamentals but HDFC Bank was a notable exception to this positive trend. Some key takeaways from this quarter’s results are as below:
No new stocks have been added/ exited from the KCP portfolio in the past month.


Little Champs portfolio (LCP) & Rising Giants Portfolio (RGP)
Th 3QFY24 results season panned out as expected for the portfolio companies. Little Champs portfolio with relatively higher exposure to the export oriented companies continued to witness muted earnings in 3QFY24 due to unfavourable demand-supply dynamics impacting the volumes as well as the realisation and profits. On the other hand, Rising Giants portfolio’s earnings was a mixed bag with growth in the domestic oriented companies more than offsetting the weak earnings of exports/chemical oriented portfolio companies. On the positive front, the management for most portfolio companies indicated a bottoming out of destocking cycle that has been impacting the earnings in the recent quarters. We are indeed seeing some corroboration of the same in the exports data (deceleration in volumes/realisation seems to be bottoming out in the last 2-3 months’ exports data). As we head into FY25, more particularly for the Little Champs portfolio, the earnings would also benefit from a favourably base of FY24. Lastly, any positive development (cut) on interest rates can be an icing on the cake in terms of significant improving the consumer sentiments for the stocks with global market exposure.
We continue to reteirate that: (i) the above factors are transient in nature and we remain sanguine about the medium-long term prospects of our portfolio companies – we can seen several cycles in the past when portfolio earnings have come back sharply after temporary period of weakness; and (ii) given the current valuation levels, any uptick in earnings can result in disproportionate gains in the share prices for the portfolio companies.
Changes to the Little Champs portfolio
Exit from Home First Finance Company:
Home First Finance’s business continues to do well with the company achieving 15%+ RoEs (vs. 11-12% when it entered our portfolio) and healthy growth, however we believe that its valuation (~4.5x FY24 P/B at our exit share price) offers little margin of safety at current levels.


Regards,
Team Marcellus
If you want to read our other published material, please visit https://marcellus.in/